Objective: Study analyzes mutation in mtDNA (Mitochondrial DNA) among diabetic women with PCOS in non-diabetic diabetic women and compared with the healthy control. Women with known case of hyperandrogenism, ovulatory dysfunction and/or polycystic ovaries were selected and anthropometric and demographic variables were collected during their clinical visit. Biochemical estimation of glucose, FSH, LH, estradiol (E2), and insulin levels were analyzed. Mutational analysis of mt-tRNA genes of each individual was compared with the updated consensus Cambridge sequence. The mtDNA content was determined in triplicate using SYBR green PCR mastermix.

Results: The clinical and biochemical characteristics of participants showed no statistical difference in age and/or FSH, PRL, E2, PRGE or fasting glucose value between patients of different groups. Women with PCOS-D had significantly higher LH, LH/FSH, TT and fasting insulin levels and HOMA-IR with respect to the control group. Ten different type of mutation were seen in POCS group. Most of these mutations were confined to evolutionarily conserved region. The mtDNA copy numbers were considerably lower PCOS group irrespective of diabetic status. To conclude, the current study inferred that the mutations occur in the mitochondrial genome, mt-tRNA in specific, are the important causal factor in PCOS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657173PMC
http://dx.doi.org/10.1186/s13104-019-4453-3DOI Listing

Publication Analysis

Top Keywords

diabetic women
8
insulin levels
8
polycystic ovary
4
ovary syndrome
4
syndrome dependency
4
mtdna
4
dependency mtdna
4
mtdna mutation
4
mutation copy
4
copy number
4

Similar Publications

Objectives: To evaluate relationship between sFlt-1/PlGF ratio, clinical characteristics and outcomes of pre-eclampsia.

Material And Methods: Retrospective analysis of 29 pregnant women with pre-eclampsia who had measured sFlt-1/PlGF ratio was conducted using electronic medical records from Obstetrics and Perinatology ward of University Hospital in Cracow.

Results: Women median age: 33.

View Article and Find Full Text PDF

The role of Anti-Müllerian hormone in women health.

Ginekol Pol

January 2025

Department of Clinical Dietetics, Faculty of Health Sciences, Medical University of Warsaw, Poland, Poland.

Anti-Müllerian hormone (AMH), also known as Müller duct inhibitory factor and primarily known for its role in sexual differentiation. In female fetuses, AMH production by granulosa cells begins around the 36th week of gestation and continues in women until menopause. It is becoming more significant in the endocrine and gynecological diagnosis of adult women.

View Article and Find Full Text PDF

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions.

Clin Endocrinol (Oxf)

January 2025

Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, 3004, VIC, Australia.

Objective: To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT).

Design: The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data.

Patients: The review focuses on MHT-related outcomes in women with natural-timed menopause captured within observational studies, RCTs, and pooled data from pivotal meta-analyses and reviews.

View Article and Find Full Text PDF

Background: Multimorbidity is a growing global concern, affecting patient outcomes and healthcare costs. In low- and middle-income countries, data on multimorbidity in primary care beyond prevalence is limited. Our study explored the demographic and clinical characteristics of multimorbidity among older people attending primary health care in Malawi.

View Article and Find Full Text PDF

Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.

Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials.

Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!